Unlike the previous five quarters, JPMorgan’s JPM trading revenues (constituting roughly 20% of its total revenues) are not expected to have improved significantly in second-quarter 2021. Since the coronavirus outbreak in mid-March 2020, client activities were remarkable and the markets witnessed unexpected volatility, which aided trading performance. However, because of market normalization and reduced volatility in the second quarter, JPMorgan’s trading business is expected to have been hurt, which is expected to dampen overall results, scheduled to be announced on Jul 13, before market open.Similar to the past few quarters, all major indexes — the S&P 500, Dow Jones and Nasdaq — witnessed an upswing in the second quarter and touched new highs. However, because of relatively low volatility in the to-be-reported quarter, equity volumes are likely to have been impacted. Thus, JPMorgan’s equity markets revenue is not expected to have improved much in the quarter.Nevertheless, the Federal Reserve’s bond-buying program is likely to have offered some support to fixed-income trading volumes. Hence, the bank’s fixed income markets revenue is likely to have been decent.At an investor conference in mid-June, JPMorgan signaled an end to the pandemic-era trading boom. The company’s CEO Jamie Dimon projected a 38% year-over-year plunge in trading revenues. He stated that the quarter under review will be “more normal” for trading business, with revenues coming in at “something a little bit north of $6 billion, which is still pretty good, by the way.”Earnings & Revenue ExpectationsFor JPMorgan, the Zacks Consensus Estimate for second-quarter 2021 earnings is pegged at $3.05, which indicates a significant rise from the prior-year quarter’s reported number. However, the consensus estimate for sales of $29.98 billion suggests a year-over-year decline of 9.1%.JPMorgan Chase & Co. Price and EPS Surprise JPMorgan Chase & Co. price-eps-surprise | JPMorgan Chase & Co. QuoteSee what other factors are expected to have influenced JPMorgan’s overall performance in the to-be-reported quarter.Our TakeContinued near-zero interest rates along with muted loan growth are expected to have hurt this Zacks Rank #3 (Hold) stock’s interest income to an extent in the to-be-reported quarter. Also, dismal trading performance along with not-so-impressive performance of the mortgage business (despite low mortgage rates) is expected to have negatively impacted the top line.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Trading Revenue Expectations of Other PlayersTrading revenues constitute a major portion of total revenues for Bank of America BAC, Citigroup C and Morgan Stanley MS. Similar to JPMorgan, dismal trading performance is likely to have adversely impacted these banks’ revenues and earnings in the second quarter. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bank of America Corporation (BAC): Free Stock Analysis Report JPMorgan Chase & Co. (JPM): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report Citigroup Inc. (C): Free Stock Analysis Report To read this article on Zacks.com click here.